Generics BulletinCould Biocon Biologics’ US settlement over Eylea (aflibercept) be the first of many? The Indian biosimilars giant has just announced that it has settled US patent litigation with Regeneron over the op
Generics BulletinThe day has finally come. Biocon Biologics has received approval for its bevacizumab biosimilar from the US Food and Drug Administration, after being delayed for several years due to facility inspecti
ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
Generics BulletinIndian biosimilars giant Biocon Biologics has struck a deal to supply US not-for-profit organization Civica with insulin aspart drug substance for final manufacturing in the US. Established in 2018, C